Get Premium to unlock powerful stock data

NAS:JAZZ (Ireland) Healthcare » Biotechnology

Jazz Pharmaceuticals PLC $ 145.67 1.67 (1.16%)

Volume:

498,331

Avg Vol (1m):

695,706

Market Cap $:

8.94 Bil

Enterprise Value $:

14.86 Bil

PE Ratio:

153.32

PB Ratio:

2.15

Also Trade In: Germany Mexico

EMBED

5D 3M YTD 1Y 3Y 5Y 10Y All 10Y -%

Above Low: +NaN%

Below High: NaN%

Financial Strength

3/10

	Current	Vs Industry
Cash-To-Debt	0.13
Equity-to-Asset	0.31
Debt-to-Equity	1.67
Debt-to-EBITDA	8.35
Interest Coverage	3.04
Piotroski F-Score	4	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.18	DISTRESS GREY SAFE
Beneish M-Score	-2.34	Not Manipulator Manipulator
WACC vs ROIC		ROIC 0.94% WACC 5.83%

Profitability Rank

8/10

	Current	Vs Industry	Vs History
Operating Margin %	17.6
Net Margin %	1.53
ROE %	1.11
ROA %	0.52
ROC (Joel Greenblatt) %	58.64
3-Year Revenue Growth Rate	16.6
3-Year EBITDA Growth Rate	1.2
3-Year EPS without NRI Growth Rate	-19.1

Warning Signs » JAZZ's Warning Signs

Valuation Rank

9/10

	Current	Vs Industry	Vs History
PE Ratio	153.32
Forward PE Ratio	8.17
PE Ratio without NRI	153.32
Shiller PE Ratio	30.18
Price-to-Owner-Earnings	35.16
PB Ratio	2.15
PS Ratio	3.2
Price-to-Free-Cash-Flow	11.84
Price-to-Operating-Cash-Flow	10.87
EV-to-EBIT	32.22
EV-to-EBITDA	18.09
EV-to-Revenue	5.7
EV-to-FCF	20.99
PEG Ratio	25.13
Current Ratio	3.35
Quick Ratio	1.93
Cash Ratio	1.01
Days Inventory	477.53
Days Sales Outstanding	56.46
Days Payable	83.15

Dividend & Buy Back

	Current	Vs Industry	Vs History
3-Year Average Share Buyback Ratio	2.1

Valuation & Return

	Current	Vs Industry	Vs History
Price-to-Intrinsic-Value-Projected-FCF	0.8
Price-to-Intrinsic-Value-DCF (Earnings Based)	4.19
Price-to-Median-PS-Value	0.53
Price-to-Peter-Lynch-Fair-Value	28.68
Earnings Yield (Greenblatt) %	3.11
Forward Rate of Return (Yacktman) %	11.93

Product

Business

Information

About

Affiliate Program

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Earn affiliate commissions by embedding GuruFocus Charts

GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed

Disclaimers

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.